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Abstract
Background: The different laboratory methods used in the diagnosis of congenital toxoplasmosis have variable
sensitivity and specificity. There is no evidence to prove that maternal treatment reduces the risk of fetal infection.
The purpose of this study was to assess methods for the confirmation of congenital toxoplasmosis after maternal
treatment with spiramycin during pregnancy, and to evaluate the effect of this treatment on clinical manifestations
of the disease in newborns (NB).
Methods: This was a community-based, cross-sectional study of acute toxoplasmosis in newborns at risk of acquiring
congenital infection. Participating newborns were born in the Clinical Hospital Maternity Ward of the Federal University
of Goiás. Eligible participants were divided into 2 groups: group 1 consisted of 44 newborns born to mothers treated
with spiramycin during pregnancy and group 2 consisted of 24 newborns born to mothers not treated with spiramycin
during pregnancy because the diagnosis of toxoplasmosis was not performed. The sensitivity and specifity of PCR for
T. gondii DNA in peripheral blood and serological testing for specific anti-T. gondii IgM and IgA, and the effects of
maternal spiramycin treatment on these parameters, were determined by associating test results with clinical
manifestations of disease.
Results: The sensitivity of the markers (T. gondii DNA detected by PCR, and the presence of specific anti-T. gondii IgM
and IgA) for congenital toxoplasmosis was higher in group 2 than in group 1 (31.6, 68.4, 36.8% and 3.7, 25.9, 11.1%
respectively). Even with a low PCR sensitivity, the group 2 results indicate the importance of developing new
techniques for the diagnosis of congenital toxoplasmosis in newborns. Within group 1, 70.4% of the infected newborns
were asymptomatic and, in group 2, 68.4% showed clinical manifestations of congenital toxoplasmosis.
Conclusions: The higher proportion of infants without clinical symptoms in group 1 (70.4%) suggests the maternal
treatment with spiramycin delays fetal infection, reducing the clinical sequelae of the disease in newborns. Given the
low sensitivity of the tests used, when there is suspicion of congenital transmission several serological and
parasitological tests are required in order to confirm or exclude congenital toxoplasmosis in newborns.
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Background
Since the discovery of Toxoplasma gondii (T.gondii) by
Alfonso Splendore in 1908, many studies have attempted to
explain its mechanisms of transmission and the host im-
mune response to the parasite, to discover drugs to inhibit
its proliferation, and to develop excellent diagnostic tech-
niques using highly sensitive and specific immune and bio-
molecular methods [1-6]. The rates of transmission and
clinical manifestation of congenital toxoplasmosis vary
sharply in newborns (NB, and depend on the immune re-
sponse of the fetus to the parasite, the gestational age when
infection took place, the parasite load in the fetal circulation
at the time of infection, the genotype of the parasite, and
the specific treatment administered to the pregnant patient
[1,2]. Clinical follow-up of cases of suspected congenital
transmission is very difficult once the pregnant woman has
been treated with spiramycin, which affects the identifica-
tion of the parasite in the NB [1,2]. In addition, tests for
anti-T.gondii IgM and IgA have poor sensitivity in fetuses
and NB [6-9]. Most infected NB (60%) are asymptomatic
[1,2]; however, they may develop severe sequelae such as
blindness or mental retardation if not treated [1,2,10-12].
It has not yet been conclusively proven that maternal treat-
ment reduces the risk of fetal infection [3,13-19], although
some studies have demonstrated a beneficial effect of treat-
ment [20-27]. Moreover, treatment with a combination of
pyrimethamine and sulphadiazine is thought to be more ef-
fective than spiramycin treatment for reducing the risk of
clinical manifestations in infected children [1,2,20-27]. There
are conflicting views in the literature regarding the effective-
ness of spiramycin treatment when the fetus has already
been infected [1,2]. However, many authors believe that spir-
amycin is able to reduce the severity of fetal infection by
delaying the onset of fetal disease and thus allowing greater
maturation of the fetal immune system [28-30].
A number of studies have evaluated the performance of
polymerase chain reaction (PCR) using amniotic fluid sam-
ples for the diagnosis of fetal infection [31-35]. In addition,
in some countries cerebrospinal fluid (CSF) is the most fre-
quently used diagnostic sample [1], while in others placental
samples are used [36]. However, few studies have attempted
to evaluate the sensitivity of PCR testing of the peripheral
blood of NB congenitally infected with T.gondii [37]. Con-
sidering the difficulty of diagnosing congenital toxoplasmo-
sis and the low frequency of clinical manifestations in
infected NB and infants, the purpose of this study was to
evaluate the influence of prenatal spiramycin treatment on
the sensitivity and specificity of diagnostic tests, and its ef-
fects on clinical manifestations of the disease in NB.
Methods
Population
This was a community-based, cross-sectional study of
acute toxoplasmosis in NB considered at risk for acquiring
congenital infection; all NB participants were born in the
Maternity Ward of the Clinical Hospital (HC) of the Uni-
versity Federal of Goiás (UFG) (Brazil) between October
2004 and December 2011. All NBs were selected by the
Maternity Protection Service of the state of Goiás and by
the Congenital Infection Control Program in the Mater-
nity Ward at HC/UFG based on their mothers having
tested positive for specific anti-T.gondii IgM and IgG dur-
ing the prenatal or postpartum periods.
Toxoplasmosis testing was performed at the first prenatal
care visit during the first gestational trimester. The preg-
nant patients were considered to have an acute infection
when presence of T. gondii-specific IgM antibodies were
confirmed and when the avidity of IgG was low (<30%), as
described by Jenum et al. [38]. All tests were performed be-
fore 16 weeks of pregnancy. Treatment of acutely infected
pregnant women began as soon as the diagnosis was deliv-
ered to the physician (15 days after the test). The state pro-
gram does not provide serological follow-up of seronegative
pregnant women, whereas the Maternity Ward at HC rou-
tinely conducts thorough toxoplasmosis testing of all NB
and their mothers. This postpartum testing detects children
with likely congenital infection, but does not indicate the
time when the acute infection occurred during the preg-
nancy. All suspected NB were closely followed for one year,
while a longitudinal study with monthly clinical and labora-
tory evaluations was being conducted. These examinations
routinely consisted of laboratory tests for toxoplasma-
specific IgG and IgM antibodies, mouse inoculation for
parasitological diagnosis of congenital toxoplasmosis, ocu-
lar fundic examinations by indirect ophthalmoscopy, and
transfontanellar ultrasonography of all infants at risk of
congenital infection. In addition to the detection of IgG
and IgM, testing for toxoplasma-specific IgA antibodies
and PCR of peripheral blood samples for identification of
T. gondii DNA were added to these examinations as part of
the study protocol.
There were 247 children born with suspected congenital
toxoplasmosis during the study period. The patients were
either the children of women with suspected acute infec-
tion during pregnancy or children whose mothers had ser-
oconverted (women previously identified as seronegative
who did not undergo seroconversion surveillance during
pregnancy). Of the 99 patients who underwent the diag-
nostic testing required by the study protocol (PCR and
testing for toxoplasma-specific IgA, IgM, IgG), 31 NB
were excluded because the diagnosis of toxoplasmosis was
not completed due to lack of clinical and laboratory moni-
toring. The tests were performed during the neonatal
period and the patients underwent clinical and laboratory
follow-up for at least one year.
From interviews with the mothers, the presence or the
absence of specific treatment with spiramycin during preg-
nancy was investigated. Forty-four of the mothers had
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been treated with 3 g of spiramycin daily, administered
over 3 doses per day (i.e. 3 × 1 g), from the time of acute
toxoplasmosis diagnosis until birth. Twenty-four mothers
had not been treated because toxoplasmosis testing was
not performed during pregnancy (these mothers served as
the control group for the treated ones). The NB were di-
vided into two groups: group 1–44 NB born to mothers
treated with spiramycin during pregnancy; and group 2–
24 newborns born to mothers who did not receive spira-
mycin treatment during pregnancy.
The study was approved by the Human and Animal Ex-
perimentation Ethics Committee of the HC/UFG (protocol
n. 092/2001 and protocol n. 024/2010) and the mothers of
the NB who agreed to participate in the study gave their in-
formed consent after they had been informed of the im-
portance of the research Figure 1.
Criteria for the diagnosis of congenital toxoplasmosis
The Program for Congenital Infection Control at the HC
Maternity Ward of UFG performs clinical follow-up from
birth until at least 12 months of age of all infected NB and
those with suspected congenital toxoplasmosis. A patient
is considered infected when:
 T. gondii is detected in peripheral blood or CSF by
mouse inoculation or T. gondii DNA is detected
by PCR;
 specific anti-T.gondii IgA and/or IgM is identified in
fetal or NB blood;
 specific antibodies (IgG and/or IgM) are found in
the CSF of the NB;
 fetal or NB T. gondii-specific IgG is 4X greater than
maternal IgG;
 NB specific anti-T. gondii IgG levels increase, or
remain positive after 12 months of life;
 the patient has clinical symptoms compatible with
congenital toxoplasmosis infection and not
explained by another diagnosis (such as Chagas
disease, syphilis, rubella, cytomegalovirus, HIV,
HTLV, hepatitis B and C), and the presence of IgG
anti T. gondii until 12 months of children's lives.
The presence of specific anti-T. gondii IgM and IgA was
confirmed using a new blood sample collected between
the fifth and tenth day of life.
Biological techniques used for the diagnosis of congenital
toxoplasmosis in the neonate
Detection of specific anti-T.gondii IgM and IgA antibodies
during serological testing, or detection of T.gondii DNA in
peripheral blood by PCR were considered to indicate con-
genital T.gondii infection.
Immunoassay
Specific anti-T.gondii antibodies were detected using several
assay systems according to the manufacturer's instructions.
Toxoplasma-specific IgG and IgM were detected by micro-
particle enzyme immunoassay (MEIA) performed using an
247 NB with suspected congenital toxoplasmosis    
148 NB                                                                                99 NB
(non-PCR methods used for the diagnosis (PCR, specific anti- T. gondii IgA, IgG and IgM)
of congenital toxoplasmosis, such as mouse  
inoculation)
excluded                                    68 NB included 31 NB excluded
44 NB                                         24 NB
(mother treated with spiramycin)               (mother not treated with spiramycin)
(The NB were excluded because
the diagnosis of toxoplasmosis
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AXsYM immunoassay system (Abbott Laboratories) and an
Architect i4000 (Abbott Laboratories) with Chemi-Flex
technology. IgM was also detected by enzyme-linked
fluorescent assay (ELFA) performed using a VIDAS
immunoanalyzer (Biomérieux). IgA was detected using an
antibody-capture enzyme immunoassay.
PCR
Peripheral blood was collected from the NB before treat-
ment with sulfadiazine, pyrimethamine, and folinic acid
commenced. A Pure Link Genomic Purification kit (Invi-
trogen) was used to extract the DNA according to the
manufacturer’s specifications. The PCR reactions were
performed in a MasterCycler Personal thermocycler. The
amplification process consisted of an initial denaturation
at 94°C (5 min), 35 cycles of denaturation at 94°C (1 min),
annealing at 62°C (1 min) and extension at 72°C (1 min),
followed by a final extension at 72°C (10 min). The PCR
reactions were performed in duplicate, using a sequence
of the B1 gene of T.gondii as the target sequence. The fol-
lowing primers were used: Toxo-B5 (5’-TGA AGA GAG
GAA ACA GGT GGT CG-3’) and Toxo-B6 (5’-CCG
CCT CCT TCG TCC GTC GTA-3’). The PCR products
were separated by electrophoresis in a 6% polyacrylamide
gel and visualized after staining with silver nitrate [39].
Peritoneal fluid from mice infected with the RH strain of
T. gondii was used as a positive control.
Statistical analysis
The data were entered into Microsoft Excel 2007 and uni-
variate analysis was conducted using Epi Info version 3.3.2.
The associations between each variable collected were
tested and P values < 0.05 were considered statistically sig-
nificant, using confidence intervals of 95%. The Fisher's
Exact Test was performed when the frequency was less
than 5.
A standardized form was used for data collection. The
information collected included: maternal data (type of
treatment, when the diagnostic testing was performed and
the instructions given by the physician to seronegative pa-
tients regarding prophylactic measures); NB clinical data
(signs of a possible congenital infection); and NB labora-
tory data (detection of T.gondii DNA by PCR analysis or
specific anti-T.gondii IgM and IgA antibodies).
The sensitivity and specificity of the laboratory tests were
determined for both groups of infants. Statistical analysis
was performed in order to verify the existence of an associ-
ation between laboratory markers of congenital infection
with maternal treatment and with the presence or absence
of clinical manifestations of the disease in the NB.
Results
Congenital toxoplasmosis was confirmed in 61.4% (27/
44) of the NB in group 1 and 79.2% (19/24) of the NB in
group 2. Women from group 1 had received prenatal treat-
ment for toxoplasmosis and almost all of these women had
undergone serological testing during the first trimester be-
cause of suspicion of acute toxoplasmosis. The women
from group 2 who had been seronegative for toxoplasmosis
during first trimester screening had probably seroconverted
during the 2nd or 3rd trimester. Of the mothers in group 2
who gave birth to infected NB, 89.5% (17/19) had been
seronegative for T. gondii during the first 3 months of preg-
nancy and 10.5% (2/19) had not undergone prenatal toxo-
plasmosis testing. None of these seronegative pregnant
women were screened for seroconversion during preg-
nancy; and the patients reported that they had not been
informed of prophylactic measures to prevent infection by
T.gondii.
Laboratory markers of congenital infection (T.gondii
DNA or T. gondii-specific IgM and IgA antibodies) were
more frequently detected in infected NB from group 2.
However, treatment with spiramycin did not interfere sig-
nificantly with laboratory detection of congenital T.gondii
infection (Table 1). The sensitivity of the laboratory tests
was higher for infants in group 2, while the specificity was
similar for both groups (100%).
Examination of infected NB revealed that clinical mani-
festations of congenital toxoplasmosis occurred in 29.6%
of infants in group 1 and 68.4% of infants in group 2
(Table 2). Treatment of pregnant women with spiramycin
significantly decreased the occurrence of hydrocephalus,
neurological impairment, and retinal lesions.
The presence of serological markers for toxoplasmosis
was not associated with greater severity of congenital
infection.
Table 1 Positivity of biological markers of congenital
toxoplasmosis in infected newborns from mothers
treated with spiramycin (Group 1) and from untreated
mothers (Group 2)
Group 1 Group 2 pa
Infected (N = 27) Infected (N = 19)
n% Sensibility (%) n% Sensibility (%)
PCR 1 (3,70) 3,7 6 (31,58) 31,58 0,053
Positive
Negative 26 (96,30) 13 (68,42)
IgM 7 (25,93) 25,93 13 (68,42) 68,42 0,0662
Positive
Negative 20 (74,07) 6 (31,58)
IgA 3 (11,11) 11,11 7 (36,84) 36,84 0,0969
Positive
Negative 24 (88,89) 12 (63,16)
aFisher’s Exact Test.
(Goiânia-GO, Brazil, 2012).
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Discussion
In Goiânia (2003), Avelino et al. [40] found one of the
highest rates of toxoplasmosis seroconversion during
pregnancy described in the literature (8.6%). This result
led to the introduction of a public program to control
toxoplasmosis during pregnancy in the state of Goiás. Al-
though the treatment of toxoplasmosis in pregnancy is
not followed by a reduction in its transmission to the fetus
[13-16], it has been shown that treatment can reduce the
severity of fetal infection [17-27] as we found in this study.
However, in our study as in others [11,14,18], some chil-
dren born to treated mothers developed ocular or neuro-
logical sequelae to congenital infection. However, severe
clinical manifestations of congenital infection were found
only among children born to untreated women (Table 2).
Our results highlight flaws in the implementation of pri-
mary prophylactic measures for seronegative women at
risk of becoming infected by T. gondii. Of the mothers in
group 2, 89.5% gave birth to infected children. Moreover,
they were not informed of possible prophylactic measures.
In France, implementation of a prevention program and
screening of pregnant women led to a reduction of symp-
tomatic neonates [24]. Preventive measures should be
taken throughout prenatal care (by doctors or the health-
care professional team). Additional information on how to
prevent the occurrence of acute infection during preg-
nancy should be provided. Simple measures such as avoid-
ing undercooked meat, eggs and raw vegetables; not
drinking untreated water or unpasteurized milk; using hy-
gienic gardening practices; and limiting interaction with
cats can help to prevent infection [41]. Failure to provide
information on primary prophylaxis measures, and the
lack of seroconversion surveillance during prenatal care,
were responsible for the high incidence of congenital in-
fection among NB born to the initially seronegative preg-
nant women of group 2. There is a high possibility of
contact between pregnant women and the sources of the
parasite in our environment [40]. In addition to failure of
primary prophylaxis, the initially seronegative women in
this study did not undergo the seroconversion surveillance
by monthly serologic screening that is indicated in regions
with a high prevalence of toxoplasmosis [1,2,42,43]. Thus,
many women were acutely infected but not properly diag-
nosed and treated.
Of the children in group 2 (untreated mothers), 68.4%
(13/19) were born with severe clinical conditions (Table 2).
In contrast, only 29.6% of the NB in group 1 were symp-
tomatic and none had severe clinical disease. Thirteen
children required tertiary prophylactic measures as their
mothers had been untreated. They needed to be followed
by a multidisciplinary team and the cost was estimated to
be exorbitant for the government program. According to
Remington et al. [1], such costs could reach a million US
dollars during the lifetime of a patient. This could have
been alleviated if those women had followed prophylactic
measures against T.gondii and had also undergone sero-
conversion surveillance. Only 10.5% (2/19) of the un-
treated women had not undergone prenatal care.
The higher percentage of infants without clinical symp-
toms in group 1 (70.3%) compared to group 2 (31.5%) sug-
gests that maternal treatment with spiramycin reduced the
fetal load of T.gondii, thus minimizing the sequelae of con-
genital toxoplasmosis infection [28-30]. Research con-
ducted by Andrade et al. [44] showed that 60% of infants
born to treated mothers were asymptomatic, which is
similar to our results. However, NB outcomes after mater-
nal spiramycin treatment are variable within the literature,
with results ranging from no benefit [13-15] to reduced
severity of congenital infection [17-27]. A European multi-
center study [14] concluded that spiramycin was of no
benefit in reducing the severity of fetal infection. However,
recent studies have shown that early treatment can inter-
fere with the transmission of infection, and decrease the
severity of congenitally acquired toxoplasmosis [23-25]. A
review by Wallon et al. [3] reported conflicting results
within the literature; five studies showed that maternal
treatment reduced the severity of vertical transmission,
but this was not confirmed in another four studies. Still
other studies, such as that by Foulon et al. [13], have
shown that early treatment was able to reduce the severity
of the clinical consequences of congenital infection, but
not vertical transmission to the fetus. Hohlfeld et al. [12]
demonstrated that treatment slightly reduced the severity
of congenital infection.
Table 2 Frequency of clinical manifestations of congenital
toxoplasmosis in newborns from mothers treated with
spiramycin (Group 1) and from untreated mothers (Group 2)
Any of the following
clinical signs
Group 1 Group 2 pa
(N = 27) (N = 19)
n% n%
Presence 8 (29,63) 13 (68,42) 0,0963
Cerebral calcification 1 (3,70) 3 (15,79) 0,2190
Hydrocephalus - 5 (26,32) 0,0181
Microcephaly - 2 (10,53) 0,1862
Blindness - 2 (10,53) 0,1862
Chorioretinitis 1 (3,70) 3 (15,79) 0,2190
Corticosubcortical dysfunction 2 (7,40) 3 (15,79) 0,3677
Systemic toxoplasmosis - 1 (5,26) 0,4255
Optic neuropathy - 4 (21,05) 0,0384
Hepatosplenomegaly - 2 (10,53) 0,1862
Hearing dysfunction 4 (14,80) 1 (5,26) 0,3402
Generalized lymphoglandular form 1 (3,70) - 0,5957
aFisher’s Exact Test.
(Goiânia-GO, Brazil, 2012).
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For the infected children whose mothers were not treated
it was not possible to determine when maternal infection
took place. Severe neurological lesions were observed only
among the children of untreated mothers, suggesting that
maternal treatment contributed to a decrease in the devel-
opment of severe neurological lesions. The same result was
shown by the European Multicenter Study [45]. However,
Cortina-Borja et al. [46], found no reduction in the severe
neurological sequelae affecting children of acutely infected
mothers, regardless of whether maternal treatment con-
sisted of spiramycin or the combination of pyrimethamine
and sulfadiazine. Those authors report that 31% of the chil-
dren born to mothers acutely infected by T. gondii during
pregnancy had severe neurological sequelae. This is a higher
percentage than reported in regions that do not have pre-
ventive government programs, indicating a more aggressive
strain of toxoplasmosis circulating in this environment [46].
The severity of the infection was greatest in NB from
group 2; 68.4% were symptomatic at birth and developed
severe manifestations of congenital toxoplasmosis: 4
(30.8%) had neuro-optical lesions, 2 (15.4%) blindness, 5
(38.5%) hydrocephalus, 2 (15.4%) microcephaly, and 1
(7.7%) systemic toxoplasmosis. Gilbert et al. [26], showed
that the risk of being born with clinical signs of congenital
infection, or developing signs until the age of three years,
is lower in countries in which intensive treatment of preg-
nant women is performed, such as in Austria.
Olariu et al. [47] reported a clinical picture as severe as
that found in Goiania for untreated children. One or more
severe clinical manifestations of congenital toxoplasmosis
were reported in 84% of the affected infants. These mani-
festations included eye lesions (92.2%), brain calcifications
(79.6%), and hydrocephalus (67.7%). In 61.6% of the in-
fants, eye lesions, brain calcifications, and hydrocephalus
were present simultaneously. Soares et al. [48] found that
72.4% of patients appeared asymptomatic at birth, but
34.5% had chorioretinitis, 32.3% had intracranial calcifica-
tion, and 42.9% had neuromotor delay.
Hearing dysfunction was observed in five NB in our
study, 4 (14.8%) from group 1 and one (5.3%) from group
2 (Table 2). Andrade et al. [44] found auditory dysfunction
in six children with congenital toxoplasmosis, two of
whom were born to mothers who were properly treated
for toxoplasmosis during pregnancy. These data suggest
that congenital toxoplasmosis, even in the absence of
other clinical manifestations, should be considered in the
evaluation of children with hearing loss, and that maternal
treatment does not exclude the possibility of developing
this dysfunction. Brown et al. [49] reported hearing im-
pairment in 28% of children born to untreated mothers;
however, in our study there was a higher incidence of
hearing loss in the treated group.
The sensitivity of serological diagnostic markers of
congenital toxoplasmosis in NB (T. gondii-specific IgM
and IgA antibodies and PCR evidence of T. gondii DNA)
reported in the literature is low, with independent studies
reporting different results (1,2,6–9,32–36). Diagnosis
seems to be adversely affected by maternal treatment as
reported by Gilbert et al. [9]. In our study, Toxoplasma
gondii was not detected by PCR in 96.3% (26/27) of sam-
ples from NB born to treated mothers, indicating that
spiramycin treatment reduced the sensitivity of this tech-
nique. A similar phenomenon was reported by Rodrigues
et al. [50], Fricker Hidalgo et al. [51] and Bessières et al.
[8]. There was also low PCR sensitivity (31.6%) in group 2
NB, suggesting that peripheral blood may not be the best
biological sample to use for the diagnosis of congenital
toxoplasmosis. Sterkers et al. found an even lower per-
centage (21.2%) of PCR-positive congenitally infected NB
in 2012 [31], and in 2001 Bessières et al. reported levels
similar to those we found in this study [8]. The identifica-
tion of the parasite in the amniotic fluid is easier than its
detection in the NB, thus the sensitivity of the diagnostic
technique (either PCR or mouse inoculation) is greater
when there is intrauterine parasitemia. Spalding et al. [52]
suggest that the low sensitivity of PCR for the diagnosis of
NB with congenital T. gondii infection relative to its high
sensitivity when used to test amniotic fluid is due to the
transient persistence of T.gondii in peripheral blood
[9,33-35]. However, according to Okay et al. [53], the am-
niotic fluid from only 40.47% of congenitally infected NB
was PCR-positive [53]. However, despite these difficulties,
PCR can be highly sensitivity (around 90%) if it is used to
test amniotic fluid collected close to the time that the
pregnant woman seroconverted, which is the time of acute
fetal infection [1,2,9,32-35]. Bessières et al. [8] found a
PCR sensitivity of 43% when using umbilical cord blood,
which is higher than the sensitivity that we report for per-
ipheral blood.
The sensitivity of specific anti-T.gondii IgM and IgA
antibodies in NB of both groups (43.5 and 21.7%, re-
spectively) was similar to that observed in other studies.
Pinon et al. [7] found the sensitivity of anti-T.gondii
IgM and IgA in NB samples to be approximately 25%.
Naessens et al. [54] reported a sensitivity of 40% for
IgM. Bessières et al. [8] found greater sensitivities for
IgA (60%) and IgM levels (50%) than those found in this
study. Foulon et al. [13] found positive results for IgA
(58%) and IgM (54%) using the enzyme-linked im-
munosorbent assay (ISAGA). In a study involving 14
laboratories supported by the European Community
Biomed 2 program, Pinon et al. [55] evaluated im-
munologic methods for the postnatal diagnosis of con-
genital toxoplasmosis and compared ELFA with a
commercial enzyme immunoassay (EIA) or in-house
immunosorbent agglutination assay (ISAGA) for the
detection of IgM or IgA. The results were highly sensi-
tive when the techniques were combined.
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Treatment of pregnant women with spiramycin did not
interfere, from a statistical viewpoint, with the sensitivity
of specific anti-T.gondii IgM and IgA antibodies in NB
within the 2 groups (Table 1). This is similar to the find-
ings of other studies [8]. However, the sensitivity was
higher (68.4% for IgM and 36.8% for IgA) in infants from
group 2, similar to the findings of Lebech et al. [56]. It is
likely that maternal treatment reduced the parasite load
transmitted to the fetus, consequently reducing antigenic
stimulation and the fetal humoral immune response. This,
along with delayed fetal disease, may be one of the reasons
for the reduced incidence of neuro-optical lesions and
hydrocephalus in babies born to treated mothers.
Detection of specific anti-T.gondii IgA did not improve
early diagnosis of congenital toxoplasmosis in the study
group, because in 90% (9/10) of the infants with anti-T. gon-
dii IgA, IgM was also present. However, IgA seemed to be
the marker with the poorest prognosis for the congenital in-
fection, as it was present in all NB who developed the
neuro-optical form of toxoplasmosis (8.7% or 4/46). The
presence of other serological markers for toxoplasmosis was
not associated with greater severity of congenital infection.
The high specificity of the laboratory markers for con-
genital toxoplasmosis (PCR, specific IgM and IgA) ob-
served in this study reinforces the need for such
procedures to be performed in the routine diagnosis of
congenital infection. They add parameters to confirm the
diagnosis and need for subsequent treatment, which uses
toxic drugs in patients suspected of congenital infection.
The effectiveness of treating pregnant women in order to
prevent fetal infection is highly controversial [12-27]; how-
ever, our results suggest that treatment of the mother reduces
the severity of fetal infection. The poor prognosis observed in
infected group 2 NB suggests that the guidelines of the Pro-
gram for Congenital Infection Control from France [57,58]
should be followed, including monthly serologic testing
throughout pregnancy for seronegative patients and a focus
on earlier medical treatment using sulfadiazine, pyrimeth-
amine and folinic acid instead of spiramycin [1,2,12,18-27] in
case of proven fetal infection. Earlier diagnosis and treatment
may prevent vertical transmission and the treatment of preg-
nant women identified as having recent toxoplasmosis can
reduce the severity of the fetal infection [24,25].
Limitations of the study
Randomized controlled trials on pregnant women, which
could provide higher statistical weight to this research,
were not performed due to ethic reasons. Not with stand-
ing, the scientific knowledge still holds very conflicting
opinions toward the effectiveness of various treatments.
We hope this work demonstrates that spiramicin can also
be useful in reducing the seriousness of the fetal infection,
as previously indicated by previous work that have been
recently very criticized.
Conclusions
Spiramycin treatment of women with acute toxoplasmosis
did not interfere significantly with the detection of labora-
tory markers of congenital toxoplasmosis. Treatment did
reduce the frequency of the clinical manifestations in the
NB, minimizing the severity of the congenital infection.
The detection of laboratory markers for congenital in-
fection was positively correlated with the clinical diagnosis
of toxoplasmosis in NB from both groups. However, due
to the low sensitivity of the laboratory markers, negative
results do not exclude the possibility of congenital infec-
tion. These results emphasize the importance of clinical
follow-up of NB suspected to have congenital toxoplasmo-
sis until at least 12 months of age.
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